The Effect of Liver Microsomal Enzyme Inducing and Inhibiting Drugs on Insulin Mediated Glucose Metabolism in Man

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1986 Jan 1

PMID 3511933

Citations 5

Authors

J T Lahtela

B Gachalyi

S Eksyma

A Hamalainen

E A Sotaniemi

Affiliations

Soon will be listed here.

Abstract

The effects of hepatic microsomal enzyme inducing (phenobarbitone and flumecinol), and inhibiting (cimetidine) drugs, and placebo treatment on insulin mediated glucose metabolism (M) were investigated in 29 healthy volunteers. Phenobarbitone (50 mg for 10 days) increased M (30%), metabolic clearance rate of glucose (MCRg), and antipyrine clearance rate (33%). Fasting immunoreactive insulin (IRI) decreased while fasting blood glucose (BG) remained unaltered. Flumecinol, another inducer, tested in two doses (200 mg and 600 mg for 6 days), did not alter glucose or antipyrine metabolism. Fasting IRI reduced on treatment with 600 mg of flumecinol, but not with the smaller dose. Cimetidine (600 mg for 6 days) decreased M (19.5%), MCRg (26%), and antipyrine clearance rate (20%). The placebo did not alter glucose or antipyrine metabolism. The results indicate that the insulin mediated glucose disposal rate can be altered by drugs influencing hepatic microsomal enzyme activity.

Citing Articles

Impact of immobilization technology in industrial and pharmaceutical applications.

Hassan M, Yang Q, Xiao Z, Liu L, Wang N, Cui X 3 Biotech. 2019; 9(12):440.

PMID: 31750038 PMC: 6841786. DOI: 10.1007/s13205-019-1969-0.

Elimination of endoplasmic reticulum stress and cardiovascular, type 2 diabetic, and other metabolic diseases.

Luoma P Ann Med. 2012; 45(2):194-202.

PMID: 22928964 PMC: 3581057. DOI: 10.3109/07853890.2012.700116.

Gene-activation mechanisms in the regression of atherosclerosis, elimination of diabetes type 2, and prevention of dementia.

Luoma P Curr Mol Med. 2011; 11(5):391-400.

PMID: 21568932 PMC: 3282906. DOI: 10.2174/156652411795976556.

Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Thunell S, Pomp E, Brun A Br J Clin Pharmacol. 2007; 64(5):668-79.

PMID: 17578481 PMC: 2203267. DOI: 10.1111/j.0306-5251.2007.02955.x.

Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).

OByrne S, Feely J Drugs. 1990; 40(2):203-19.

PMID: 2226212 DOI: 10.2165/00003495-199040020-00003.

References

Beck-Nielsen H, Pedersen O, Lindskov H . Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh). 1979; 90(1):103-12. DOI: 10.1530/acta.0.0900103. View

Remmer H, Merker H . [Enzyme induction and increase of endoplasmic reticulum in liver cells during phenobarbital (Luminal) therapy]. Klin Wochenschr. 1963; 41:276-82. DOI: 10.1007/BF01483392. View

Serlin M, Sibeon R, Mossman S, Breckenridge A, Williams J, Atwood J . Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979; 2(8138):317-9. DOI: 10.1016/s0140-6736(79)90340-4. View

DeFronzo R, Tobin J, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237(3):E214-23. DOI: 10.1152/ajpendo.1979.237.3.E214. View

Nordlie R . Multifunctional glucose-6-phosphatase: cellular biology. Life Sci. 1979; 24(26):2397-404. DOI: 10.1016/0024-3205(79)90447-8. View

Kolterman O, Insel J, Saekow M, Olefsky J . Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest. 1980; 65(6):1272-84. PMC: 371464. DOI: 10.1172/JCI109790. View

Proietto J, Alford F, DUDLEY F . The mechanism of the carbohydrate intolerance of cirrhosis. J Clin Endocrinol Metab. 1980; 51(5):1030-6. DOI: 10.1210/jcem-51-5-1030. View

Puurunen J, SOTANIEMI E, Pelkonen O . Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol. 1980; 18(2):185-7. DOI: 10.1007/BF00561588. View

Caro J, Amatruda J . Insulin receptors in hepatocytes: postreceptor events mediate down regulation. Science. 1980; 210(4473):1029-31. DOI: 10.1126/science.7001632. View

10.

Czech M . Insulin action. Am J Med. 1981; 70(1):142-50. DOI: 10.1016/0002-9343(81)90421-6. View

11.

Olefsky J, Kolterman O . Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes. Am J Med. 1981; 70(1):151-68. DOI: 10.1016/0002-9343(81)90422-8. View

12.

Feely J, Wilkinson G, Wood A . Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981; 304(12):692-5. DOI: 10.1056/NEJM198103193041202. View

13.

Olefsky J . LIlly lecture 1980. Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes. 1981; 30(2):148-62. DOI: 10.2337/diab.30.2.148. View

14.

Thurman R, Reinke L, Belinsky S, Evans R, Kauffman F . Co-regulation of the mixed-function oxidation of p-nitroanisole and glucuronidation of p-nitrophenol in the perfused rat liver by carbohydrate reserves. Arch Biochem Biophys. 1981; 209(1):137-42. DOI: 10.1016/0003-9861(81)90265-4. View

15.

DeFronzo R, Ferrannini E . The pathogenesis of non-insulin-dependent diabetes: an update. Medicine (Baltimore). 1982; 61(3):125-40. DOI: 10.1097/00005792-198205000-00001. View

16.

Pirttiaho H, Sotaniemi E, Pelkonen R, Pitkanen U . Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol. 1982; 22(5):441-5. DOI: 10.1007/BF00542550. View

17.

Reaven G . Insulin resistance in noninsulin-dependent diabetes mellitus. Does it exist and can it be measured?. Am J Med. 1983; 74(1A):3-17. DOI: 10.1016/0002-9343(83)90650-2. View

18.

Sotaniemi E, Arranto A, Stengard J, Sutinen S . Treatment of noninsulin-dependent diabetes mellitus with enzyme inducers. Clin Pharmacol Ther. 1983; 33(6):826-35. DOI: 10.1038/clpt.1983.113. View

19.

Fink R, Kolterman O, Griffin J, Olefsky J . Mechanisms of insulin resistance in aging. J Clin Invest. 1983; 71(6):1523-35. PMC: 370358. DOI: 10.1172/jci110908. View

20.

Arner P, Einarsson K, Backman L, Nilsell K, Lerea K, Livingston J . Studies of liver insulin receptors in non-obese and obese human subjects. J Clin Invest. 1983; 72(5):1729-36. PMC: 370461. DOI: 10.1172/JCI111132. View